Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Who might benefit from immunotherapy? New study suggests possible marker

While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments.

"This begs the question: Why does it work in those patients? We don't understand the mechanism at work very well," says Weiping Zou, M.D., Ph.D., the Charles B. de Nancrede Professor of Surgery, Pathology, Immunology and Biology at the University of Michigan.

Zou and colleagues offer a clue in a new study published in the Journal of Clinical Investigation.

Researchers studied mice with colon cancer, ovarian cancer, melanoma and lung cancer to understand how expression of the protein PD-L1 affects response to its blockade.

This is a key target of immunotherapy drugs.

The researchers found a key link in the antigen presenting cells - macrophages and dendritic cells found in the tumour microenvironment and in the nearby lymph nodes.

"The antigen presenting cells are the real guide. PD-L1 expression in these cells is responsible for response to therapy. This reshapes our understanding of checkpoint blockade therapies and the biomarkers that may predict clinical efficacy," Zou says.

Interestingly, his team first pinpointed the human cancer associated antigen presenting cells in 2003, in a paper published in Nature Medicine.

That paper demonstrated dendritic cells express PD-L1 and blockade of PD-L1 on antigen presenting cells causes tumour regression in model systems.

But this was when immunotherapy research was in its very early stages, before any of today's therapies were introduced.

When the Food and Drug Administration approved immunotherapy drugs designed to block PD-L1 and PD-1, the indication said patients' tumours must express PD-L1.

But these therapies have worked in patients whose tumour cells did not express PD-L1.

And they have failed in patients whose tumour cells do.

"Clearly, that's not a reliable biomarker," Zou says.

In the new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies. In both cancers, researchers found a link between the percent of antigen presenting cells expressing PD-L1 and an objective clinical response to treatment.

Currently, tumour tissue is tested broadly for PD-L1 expression.

Without looking at individual cells within the tissue, it could mask the true source of PD-L1 expression.

This study suggests a more complicated analysis looking for additional markers might be more informative in guiding treatment.

Source: Michigan Medicine - University of Michigan

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation